Theralase Technologies IncOTCQB:TLTFFView on Canadian Exchange
- LAST PRICE0.1860
- TODAY'S CHANGE (%)0.0044 (2.4229%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.1917 / 0.1816
- Day Range
- 52 Week Range
- Volume6,783
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLTFF |
|---|---|---|
| 09:57 ET | 2000 | 0.1917 |
| 10:48 ET | 1700 | 0.1833 |
| 01:32 ET | 3000 | 0.186 |
May 30, 2023
Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements, from 9:30PM ET on Tuesday May 30, 2023 by Accesswire
9:30PM ET on Tuesday May 30, 2023 by AccesswireTheralase(R) Releases 1Q2023 Interim Financial Statements, from 7:35PM ET on Tuesday May 30, 2023 by Accesswire
7:35PM ET on Tuesday May 30, 2023 by Accesswire
May 25, 2023
Theralase Re-appointed Founder Roger DuMoulin-White as President and CEO As OSC Order Has Expired, from 8:39AM ET on Thursday May 25, 2023 by MT Newswires
8:39AM ET on Thursday May 25, 2023 by MT Newswires
May 24, 2023
Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer, from 6:45PM ET on Wednesday May 24, 2023 by Accesswire
6:45PM ET on Wednesday May 24, 2023 by Accesswire
May 10, 2023
Theralase Provides Update on Phase II Bladder Cancer Study, from 7:00AM ET on Wednesday May 10, 2023 by Accesswire
7:00AM ET on Wednesday May 10, 2023 by Accesswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Theralase Technologies Inc | 52.9M | 0.0x | --- |
Company Information
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. The Company operates through two divisions, The Anti-Cancer Therapy (ACT) and The Cool Laser Therapy (CLT). ACT division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. CLT division designs, develops, manufactures and markets patented, and its laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerves, muscle and joint conditions. The Company develops products both internally and using the assistance of external resources.
Contact Information
- Headquarters
- 41 Hollinger RdEAST YORK, ON, Canada M4B 3G4
- Phone
- 416-699-5273
- Fax
- 416-699-5250
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.9M |
|---|---|
Revenue (TTM) | $1.1M |
Shares Outstanding | 216.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.74 |
EPS | $-0.03 |
Book Value | $0.01 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 46.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -459.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
